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ABSTRACT 
BACKGROUND  
Haemodialysis patients are exposed to high levels of oxidative stress, perhaps 
contributing to increased rates of cardiovascular and malignant disease. In this 
context the body’s defence mechanisms against oxidative insult, including activity 
of the antioxidant enzymes superoxide dismutase (SOD) and glutathione 
peroxidase (GPx), are known to be deranged. 
METHODS 
This randomised double-blind study assessed the effects of a novel micronutrient 
cocktail containing physiological doses of antioxidant vitamins and trace minerals 
on antioxidant enzyme activity in maintenance haemodialysis.  37 patients were 
randomised to receive placebo or micronutrient.  SOD and GPx activity was 
analysed at baseline and after six months of treatment.   
RESULTS   
SOD levels did not change in the treatment group but fell significantly (p = 
0.0443) in controls, while activity of GPx remained unchanged in controls but 
rose significantly (p = 0.0123) in treated patients.  
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CONCLUSIONS 
These results are consistent with a beneficial effect of the cocktail on antioxidant 
enzyme activity and may contribute to an indication for large scale studies to 
assess clinical outcome measures. 
 
KEYWORDS 
Antioxidant enzymes; haemodialysis; micronutrient supplementation; oxidative 
stress. 
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INTRODUCTION 
Haemodialysis patients have a much lower survival than the general population 
(1), with a huge excess cardiovascular mortality (2) and higher rates of cancer 
(3).  Antioxidant status is disordered in chronic kidney disease (4) and 
haemodialysis itself promotes further oxidant insult (5).  Markers of oxidative 
stress are higher in haemodialysis patients with as opposed to without 
cardiovascular disease (6), and perhaps oxidative damage to cellular 
macromolecules contributes to the amplified risk of cardiovascular and neoplastic 
disorders. 
The organism’s defence against oxidative stress includes the antioxidant 
enzymes superoxide dismutase (SOD) and glutathione peroxidase (GPx).  Both 
these enzymes are known to be disordered in chronic kidney disease (7-10).  
Possible mechanisms include increased stimulation or exhaustion of enzyme 
systems by overwhelming oxidative challenge, altered expression of messenger 
RNA (11, 12), loss of renal functioning mass with reduction in synthetic capacity 
(13), and depletion of antioxidant vitamins or essential trace elements such as 
copper, zinc and selenium (8, 14) because of inadequate intake or excess 
removal by dialysis. 
To investigate whether replenishment of physiological doses of trace elements 
and antioxidant vitamins could ameliorate this enzyme derangement, we studied 
the effects of a micronutrient cocktail (MNC) on SOD and GPx activity in 
maintenance haemodialysis patients. 
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SUBJECTS AND METHODS 
The study received full ethical approval from the Office of Research Ethics 
Committees of Northern Ireland (ORECNI) and was conducted in adherence with 
the Declaration of Helsinki. 
Adult subjects were recruited by interview, detailed information leaflet and 
signed informed consent from the haemodialysis populations programmes at 
Tyrone County Hospital, Omagh, and Altnagelvin Hospital, Derry/Londonderry, 
Northern Ireland.  Exclusion criteria are shown in Table 1.  39 subjects in total 
were enrolled in the study.  
 
All patients received thrice weekly haemodialysis against biocompatible 
membranes with the dialysis prescription adjusted to deliver a Kt/V of 1.2 or 
higher.  All received erythropoesis stimulating agents (epoetin alfa or 
darbepoetin alfa) to maintain haemoglobin according to Renal Association 
standards.  Renal Association targets for calcium, phosphate and parathyroid 
hormone were maintained with phosphate binders and vitamin D analogues and, 
where required, cinacalcet according to NICE guidelines.  Low dose parenteral 
iron was administered to maintain transferrin saturation >20%. 
 
Subjects were randomised to receive a daily capsule containing the 
micronutritional cocktail (MNC) or placebo.  The composition of the MNC is 
shown in Table 2 and is based on published recommended daily allowances in 
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the United Kingdom (15).  Doses of water soluble vitamins were adjusted slightly 
to take account of losses during haemodialysis.  The dose of folate was lower 
than these recommendations and based on published evidence of the quantity 
required to reduce plasma homocysteine levels (16).  The dose of vitamin B12, 
on the other hand, was increased to avoid any risk of B12 deficiency neuropathy 
in the context of folate supplementation. 
Concordance with medication was checked by monthly interviews and tablet 
counts.  Clinical events were logged in the electronic patient record.   
Clotted and whole blood samples (lithium heparin) were drawn predialysis at 
baseline, three months and six months.  Serum and plasma were separated 
immediately and stored frozen at –70o C before analysis.  SOD and GPx 
concentrations in red cells separated from lithium heparin samples were 
determined on the ILab650 analyser using commercially available kits from 
Randox Laboratories, Antrim, UK. 
Group means were compared by paired or unpaired Student’s t-test as 
appropriate or, for non-normally distributed data, by the Wilcoxon rank sum 
test.  Differences in proportions were tested by chi-square or Fisher’s exact test 
for parametric and non-parametric data respectively.  
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RESULTS 
37 of the 39 subjects enrolled into the study were randomised. Serum phosphate 
was slightly lower in the placebo arm (1.25 versus 1.49 mmol/l, p = 0.0094), but 
baseline demographic, clinical, laboratory and therapeutic features, folic acid 
status and total antioxidant capacity as measured by the Ferric Reducing Ability 
of Plasma (FRAP) assay otherwise did not differ between the groups (Tables 3a 
and 3b).  The placebo arm lost three subjects and the intervention arm four 
before completion.  30 subjects (14 in the intervention group and 16 in the 
placebo group) completed the study.  
Baseline levels of SOD (1207 iu/gHb +/- 143.1 vs 1271 +/- 163.1; p = 0.7739) 
and GPx (79.82 +/- 10.65 vs 68.97 ± 5.934; p = 0.3655) (Figure 1) did not 
differ between the groups.  Neither enzyme was influenced by age, gender, 
diabetes status, time since first dialysis, time since first renal presentation, or 
delivered dose of dialysis as Kt/V.  Mean baseline SOD (1241) was close to the 
lower limit of the population reference range (1102 – 1601).  Twelve of thirty 
subjects fell below the range. 
SOD in control subjects showed a further significant fall six months after 
initiation of the study (1271 vs 880.9, p = 0.0443) (Figure 2).  SOD in the 
intervention group, on the other hand, remained unchanged over the same 
period (1207 vs 1062, p = 0.3083).  After six months, SOD levels in control 
subjects tended to be lower than in the treated group (880.9 vs 1062, p = 
0.0688). 
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Baseline GPx, by contrast, tended to be higher (mean 74.03 iu/gHb) (Figure 3) 
than the population range (30-55), with 23 of 30 samples above the upper limit 
and only 7 lying within range. 
GPx activity in the control group did not change during the study (68.97 vs 
79.78, p = 0.1546) (Figure 4).  In the intervention group, however, GPx rose 
significantly from a mean of 79.82 to 134.60 (p = 0.0123).  After six months, 
GPx activity in the intervention group were highly significantly greater than in the 
control group (134.60 vs 79.78, p = 0.0001). 
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DISCUSSION 
Antioxidant enzymes form a crucial part of the body’s defence against oxidative 
damage.  Superoxide dismutase (SOD) is a suite of three enzymes responsible 
for catalyzing the dismutation of superoxide radicals into molecular oxygen and 
hydrogen peroxide.  SOD3 is extracellular; the intracellular enzymes are soluble 
SOD1 in the cytoplasm and mitochondria, and mitochondrial SOD2.  SOD1 is a 
homodimer binding copper and zinc and encoded by a gene at position 22.1 on 
the long arm of chromosome 21.  SOD1 knockout mice display exaggerated age-
related loss of muscle mass (17) and an increased frequency of hepatocellular 
carcinoma (18).  The homotetramer SOD2, genetically encoded at locus 6q25, 
contains manganese; lack of this enzyme in mice is fatal within a few days of 
birth (19). 
Glutathione peroxidise (GPx) is a family of eight enzymes acting downstream 
from SOD to reduce free hydrogen peroxide to water.  The most abundant 
isoform is GPx1, a homotetramer containing selenium and encoded at 3p21.3.  
GPx1 knockout mice exhibit early development of cataracts (17). 
Although there is considerable variation in reported results (20-26), our findings 
are consistent with many previous studies showing that SOD activity is reduced 
in renal failure (7-10, 27-29). This may reflect exhaustion of the enzyme system 
by exaggerated oxidant stress as well as low copper and zinc reserves (8) related 
to both dietary deficiency and increased losses across dialysis.  The maintenance 
of SOD levels in our intervention subjects, in contrast to the placebo group, 
suggests a beneficial effect of the micronutrient supplement on the enzyme 
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system, either by replenishing exhausted trace metal reserves or by a general 
amelioration of oxidative stress. 
By contrast, GPx activity in our subjects tended to be higher than in the general 
population.  It may be that the GPx system had been upregulated in our patients 
to combat the increased levels of oxidative stress associated with uraemia and 
dialysis but, as a second line of defence, had not yet become exhausted.  The 
significant increase in enzyme activity in the treated but not the placebo group 
once more supports a beneficial effect of the supplement. 
Why however should GPx activity in our subjects be higher than in the general 
population, whereas levels in dialysis patients in most previous publications have 
tended to be low (5, 8, 10, 14, 24-28, 30, 31)?  These papers include a study in 
Belfast (5) on a group of patients that, other than containing a higher proportion 
of urban dwellers, would have been constitutionally and environmentally very 
similar to our population. 
The answer is almost certainly evident within the detailed description of the 
subjects in the Belfast study.  These patients dialysed twice weekly against non-
biocompatible cellulosic membranes.  This was in an era before quality control of 
dialysis adequacy by Kt/V was commonplace and nutritional support for dialysis 
patients may also have been less advanced.  In contrast, the patients in the 
current study were on at least thrice weekly dialysis against biocompatible 
membranes with careful monitoring of dialysis adequacy and regular specialist 
nutritional assessment.  It is therefore likely that their exposure to oxidative 
stress, caused by both uraemia and by non-compatible dialysis membranes, was 
less than the Belfast cohort and probable that their nutritional reserves of trace 
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metals and anti-oxidant vitamins were greater.  Thus the discrepancy in baseline 
GPx activity is entirely comprehensible. 
We believe that the most likely explanation for the further increase in GPx 
activity after micronutrient supplementation represents an improvement in the 
ability of the enzyme system to combat continuing oxidative stress, possibly 
because of supplementation of nutrients essential for the system, including 
selenium.  We consider the alternative hypothesis, that the enhanced activity (in 
the context of supplementation of antioxidant agents) reflects an increase in 
oxidative stress to be counterintuitive and, since SOD activity was maintained in 
the active but not in the placebo group, to be less likely.  We have not as yet 
been able to measure selenium levels to provide support for this explanation. 
Total antioxidant capacity by FRAP assay at the start of the study was identical 
between the active and control groups.  We intend to derive additional 
information by measuring lipid peroxidation, but this has not yet been 
performed.   We also plan to measure oxidative DNA damage using a modified 
COMET assay and will report these results separately. 
The literature on controlled trials of the effects of dietary modification on oxidant 
stress in haemodialysis is limited.  Supplementation with folic acid reduces 
homocysteine levels, in turn a risk factor for cardiovascular disease in 
haemodialysis patients, as well as improving plasma total antioxidant capacity 
(32).  An open study of folate administration has claimed a beneficial effect (33), 
but results with vitamin B group supplementation have usually been 
disappointing: high doses of thiamine and pyridoxine did not ameliorate markers 
of oxidative stress (34) and folic acid alone (35) or with other B vitamins (36, 37) 
has not improved cardiovascular outcome (although the doses of folate used 
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were much higher than in the current study).  Combination of folate and other B 
vitamins with vitamins E and C (38) has also failed to reduce markers of 
oxidative stress. 
 
Administration of vitamin C alone to haemodialysis patients increases serum 
ascorbate levels (38) with potentially beneficial effects on malondialdehyde and 
lipid levels (40) and on plasma polypeptide characteristics (41).  A randomized 
open-label trial did not however show any benefit on inflammation or oxidative 
stress (42).  Intravenous ascorbate does seem to reduce intracellular production 
of reactive oxygen species (43) and has been combined with use of vitamin E 
coated dialysis membranes to enhance this effect (44). 
Indeed, several small studies (45-47) have suggested benefit from vitamin E 
coated dialysis membranes on various markers of oxidative damage.  A small 
randomised study (48) of oral supplementation with vitamin E confirmed changes 
in serum alfa- and gamma-tocopherol levels but was insufficiently powered to 
demonstrate amelioration of oxidative protein modifications.  Another recent trial 
(49) has shown that both oral vitamin E and concentrated red grape juice 
(containing polyphenols) reduce levels of oxidised low density lipoprotein and 
neutrophil NADPH oxidase activity and that this effect is amplified by these 
agents in combination.   
Although a further study of oral vitamin E has not shown any benefit on markers 
of microinflammation (50), a large controlled trial in haemodialysis patients with 
prevalent cardiovascular disease has demonstrated a reduction in composite 
cardiovascular endpoints and myocardial infarction (51).  Similar results have 
been reported for antioxidant therapy with acetylcysteine (52). 
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In conclusion, although the data remain relatively scant, there is emerging 
evidence that anti-oxidant therapy may improve clinical outcomes as well as 
laboratory markers of oxidative stress.  The effects of a combination of 
physiological doses of antioxidant vitamins and trace elements have not been 
described previously, and the potential of this simple intervention deserves 
further evaluation.  This carefully controlled and blinded study has demonstrated 
clearly significant effects of a unique combined micronutritional supplement on 
activity of anti-oxidant enzymes.  These results are consistent with an 
interpretation that the supplement supports enzyme systems in resisting oxidant 
stress and may provide support for further studies to determine whether this 
observation can be translated into clinical benefit for haemodialysis patients.
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TABLES 
TABLE 1 
Exclusion Criteria 
Age <18 years 
Age >80 years 
On maintenance haemodialysis therapy for <3 months 
Smoking 
Known alcohol abuse in previous 12 months 
Severe liver disease 
Severe uncontrolled cardiac or respiratory disease 
Active neoplastic disease 
Pregnancy 
Breastfeeding 
Participating in another clinical trial 
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TABLE 2 
Composition of Micronutrient Cocktail 
Supplement Dose 
Vitamin C  60 mg 
Vitamin E  10 mg 
Vitamin K 65 g 
    
Folic acid 800 g 
Vitamin B2  1.6 mg 
Vitamin B6 10 mg 
Vitamin B12 12 g 
Vitamin B5  1 mg 
Vitamin B1  1 mg 
    
Zinc 15 mg 
Copper 1.5 mg 
Selenium 75 g 
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TABLE 3a 
 
BASELINE DEMOGRAPHIC AND CLINICAL FEATURES (PROPORTIONS) 
 
 
Feature Active Group Placebo Group All p 
value* 
  N
o (%) No (%) No (%)  
Male 10 (56) 12 (63) 22 (59) 0.7431 
Female 8 (44) 7 (37) 15 (41) 
Diabetes a 7 (39) 6 (32) 13 (35) 0.7374 
Renal  
Atherosclerosis b  
1 (6) 2 (11) 3 (8) 1.0000 
Significant cardiac 
comorbidity c  
9 (50) 3 (16) 12 (32) 0.0750 
Significant peripheral 
vascular comorbidity d  
2 (11) 3 (16) 5 (14) 1.0000 
Cerebrovascular 
disease 
4 (22) 2 (11) 6 (16) 0.7140 
Chronic lung disease 3 (17) 1 (5) 4 (11) 0.4048 
Inactive neoplastic 
disease 
0 (0) 2 (11) 2 (5) 0.4865 
All antihypertensive 
therapy 
13 (72) 14 (74) 27 (73) 1.0000 
ACEi or ARB therapy 8 (44) 7 (37) 15 (41) 0.7431 
ESA therapy 18 (100) 19 (100) 37 (100) 1.0000 
Parenteral iron 
therapy 
12 (67) 17 (89) 29 (78) 0.1245 
Phosphate binders 14 (78) 10 (53) 24 (65) 0.1704 
Vitamin D analogues 15 (83) 10 (53) 25 (68) 0.0789 
Cinacalcet therapy 2 (11) 0 (0) 2 (5) 0.4872 
Statin therapy 11 (61) 12 (63) 23 (62) 1.0000 
        
 
TABLE 3a 
*Fisher’s exact test 
aincluding diabetic nephropathy as primary renal diagnosis. 
bas primary renal diagnosis. 
cactive angina, previous myocardial infarction, previous coronary intervention, episode of heart failure 
requiring hospital admission. 
dactive intermittent claudication, ischaemic rest pain, ischaemic ulcers, previous radiological or surgical 
intervention. 
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TABLE 3b 
 
BASELINE DEMOGRAPHIC AND CLINICAL FEATURES (MEANS) 
 
Feature Active Group Placebo Group All p 
value* 
  Mean (SD) Mean (SD) Mean (SD)  
Age in Years  64.50 (8.327) 63.25 (9.199) 63.83 (10.14) 0.7173 
Body Mass Index 26.91 (5.219) 26.26 (4.978) 26.56 (4.909) 0.7301 
Time on Renal 
Replacement Therapy 
(months) 
27.45 (38.86) 32.24 (60.08) 29.84 (76.87) **0.8156 
Equivalent ESA 
dosage (units per 
week) 
 6444  (3240)  6000 (2560)  6216 (2878) 0.6453  
Urea Reduction 
Ratio 
0.7378  (0.05231)  0.7363  (0.05737) 0.7370  (0.05420)  0.9360  
CRP 10.39  (9.51)  13.58 (10.19) 12.03 (9.86) 0.3323  
Total calcium 
(mmol/l) 
2.351  (0.1288)  2.361  (0.1398) 2.356  (0.1328)  0.8328  
Serum albumin 
(g/l) 
34.06  (3.096)  35.16  (4.045) 34.62  (3.608)  0.3603  
Phosphate 
(mmol/l) 
1.492  (0.2188)  1.247  (0.3132) 1.366  (0.2952)  0.0094  
Alkaline 
phosphatase 
112.8  (102.3)  94.42  (29.42) 103.4  (73.93)  **0.4712 
PTH 241.6  (115.1)  185.1  (187.5) 212.6  (157.0)  **0.2750  
Haemoglobin 
(g/dl) 
11.71  (1.461)  11.57  (0.9351) 11.64  (1.204)  0.7344  
Ferritin 621.2  (363.7)  606.2  (342.0) 613.7  (348.0)  0.8993  
Transferrin 
saturation (%) 
28.50  (9.476) 30.11  (10.69) 29.31  (9.991)  0.6354  
Total cholesterol 
(mmol/l) 
3.639  (0.5658)  3.653  (0.7389) 3.646  (0.6513)  0.9499  
-2 microblobulin 22.64  (6.939)  24.93  (7.225) 23.78  (7.011)  0.4570  
FRAP assay*** 1467 (236.6) 1453 (216.3)   NS 
Plasma folate 
(ng/ml) 
5.55 (4.42 6.29 (2.82)   NS 
Whole blood 
folate (ng/ml) 
17.05 (11.71) 19.09 (11.76)   NS 
 
*Student’s t-test 
**employing Welch’s correction 
***Ferric Reducing Ability of Plasma 
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LEGENDS FOR FIGURES 
 
Figure 1:   Baseline Superoxide Dismutase Levels 
 
Figure 2: Change in Superoxide Dismutase in Control (p = 0.0443) and 
Active (p = 0.3083) Groups (Student’s t-test). 
 
Figure 3:  Baseline Glutathione Peroxidase Levels 
 
Figure 4:  Change in Glutathione Peroxidase levels in Control (p = 0.1546) 
and Active (p = 0.0123) Groups (Student’s t-test). 
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